Unicycive Therapeutics (Unicycive Therapeutics) 3-Year Book Growth Rate : 21.50% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Unicycive Therapeutics 3-Year Book Growth Rate?

Unicycive Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $-0.65.

During the past 3 years, the average Book Value per Share Growth Rate was 21.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 5 years, the highest 3-Year average Book Value per Share Growth Rate of Unicycive Therapeutics was 21.50% per year. The lowest was 20.20% per year. And the median was 20.85% per year.

Competitive Comparison of Unicycive Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Unicycive Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unicycive Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Unicycive Therapeutics's 3-Year Book Growth Rate falls into.

Unicycive Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Unicycive Therapeutics (NAS:UNCY) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Unicycive Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Unicycive Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Unicycive Therapeutics (Unicycive Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unicycive Therapeutics Inc (NAS:UNCY) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

4300 El Camino Real, Suite 210, Los Altos, CA, USA, 94022

Website

https://www.unicycive.com

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

Executives

Sandeep Laumas	director	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
John L Ryan	director	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Sara Kenkare-mitra	director	C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gaurav Aggarwal	director	C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Douglas Jermasek	other: EVP of Corporate Strategy	4300 EL CAMINO REAL, SUITE 210, LOS ALTOS CA 94022
Brigitte Schiller	director	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
John Townsend	officer: Chief Financial Officer	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Pramod Gupta	officer: EVP, Pharmaceuticals and BD	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
Shalabh K. Gupta	director, officer: CEO	UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022